Batefenterol/fluticasone furoate

Drug Profile

Batefenterol/fluticasone furoate

Alternative Names: '081/FF; 961081 + fluticasone furoate; FF/'081; FF/GSK-961081; Fluticasone furoate/batefenterol; Fluticasone furoate/GSK-961081; Fluticasone furoate/TD-5959; GSK-961081/FF; GSK-961081/fluticasone furoate; TD-5959/fluticasone furoate

Latest Information Update: 23 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline; Theravance
  • Developer GlaxoSmithKline
  • Class Androstadienes; Biphenyl compounds; Bronchodilators; Carbamates; Carboxylic acids; Glucocorticoids; Piperidines; Quinolines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in United Kingdom (Inhalation, Powder)
  • 01 Jul 2016 GlaxoSmithKline completes a phase IIa trial for Chronic obstructive pulmonary disease in USA (NCT02573870)
  • 01 Jan 2016 Phase-II clinical trials in Chronic obstructive pulmonary disease in USA (Inhalation) (NCT02573870)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top